These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 19104179)

  • 1. CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.
    Dietrich W; Nicklisch S; Koster A; Spannagl M; Giersiefen H; van de Locht A
    Anesthesiology; 2009 Jan; 110(1):123-30. PubMed ID: 19104179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
    Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
    Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery.
    Szabó G; Veres G; Radovits T; Haider H; Krieger N; Bährle S; Miesel-Gröschel C; Niklisch S; Karck M; van de Locht A
    J Thorac Cardiovasc Surg; 2010 Jan; 139(1):181-8; discussion 188. PubMed ID: 20106364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
    Longstaff C
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):537-42. PubMed ID: 7531000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.
    Stassen JM; Lambeir AM; Matthyssens G; Ripka WC; Nyström A; Sixma JJ; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):646-54. PubMed ID: 8585001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on the anticoagulant properties of natural protease inhibitors].
    Schulz K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1967; 88(2):225-35. PubMed ID: 4174663
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents.
    Flight S; Johnson L; Trabi M; Gaffney P; Lavin M; de Jersey J; Masci P
    Pathophysiol Haemost Thromb; 2005; 34(4-5):188-93. PubMed ID: 16707925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.
    Vadivel K; Kumar Y; Ogueli GI; Ponnuraj SM; Wongkongkathep P; Loo JA; Bajaj MS; Bajaj SP
    J Thromb Haemost; 2016 Dec; 14(12):2509-2523. PubMed ID: 27797450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
    Day JR; Haskard DO; Taylor KM; Landis RC
    Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
    Tanaka KA; Szlam F; Levy JH
    Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors.
    Swedberg JE; Harris JM
    Biochemistry; 2011 Oct; 50(39):8454-62. PubMed ID: 21877690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
    Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
    Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel synthetic serine protease inhibitor CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model.
    Szabó G; Veres G; Radovits T; Haider H; Krieger N; Bährle S; Niklisch S; Miesel-Gröschel C; van de Locht A; Karck M
    J Thorac Cardiovasc Surg; 2010 Mar; 139(3):732-40. PubMed ID: 20176215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
    Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM
    Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
    Tanaka KA; Szlam F; Katori N; Vega JD; Levy JH
    Thromb Res; 2004; 113(5):333-9. PubMed ID: 15183046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
    Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of coagulation and fibrinolysis by aromatic amidino compounds. An in vitro and in vivo study.
    Geratz JD
    Thromb Diath Haemorrh; 1971 Jun; 25(3):391-404. PubMed ID: 5314899
    [No Abstract]   [Full Text] [Related]  

  • 19. [The effect of aprotinin and tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass].
    Risch A; Dorscheid E; Stein G; Seyfert UT; Grundmann U
    Anaesthesist; 2000 Apr; 49(4):279-85. PubMed ID: 10840537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprotinin, an antifibrinolytic drug, attenuates bradykinin-induced permeability in conscious rats via platelets and neutrophils.
    O'Brien JG; Battistini B; Farmer P; Johnson RJ; Zaharia F; Plante GE; Sirois P
    Can J Physiol Pharmacol; 1997 Jun; 75(6):741-9. PubMed ID: 9276158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.